Taiwan - Delayed Quote TWD

GenMont Biotech Incorporation (3164.TW)

20.20
+0.10
+(0.50%)
At close: May 9 at 1:30:38 PM GMT+8
Loading Chart for 3164.TW
  • Previous Close 20.10
  • Open 20.20
  • Bid 20.20 x --
  • Ask 20.30 x --
  • Day's Range 19.90 - 20.30
  • 52 Week Range 17.20 - 25.35
  • Volume 40,197
  • Avg. Volume 77,668
  • Market Cap (intraday) 1.748B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 44.89
  • EPS (TTM) 0.45
  • Earnings Date --
  • Forward Dividend & Yield 0.80 (3.96%)
  • Ex-Dividend Date Mar 27, 2025
  • 1y Target Est --

GenMont Biotech Incorporation engages in the research, development, manufacture, and sale of functional probiotic supplements in Taiwan. The company offers functional probiotics raw materials, capsules, powder, tablets, and liquid products; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.

www.genmont.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3164.TW

View More

Performance Overview: 3164.TW

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

3164.TW
3.69%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
9.20%

1-Year Return

3164.TW
7.64%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.72%

3-Year Return

3164.TW
13.12%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
30.32%

5-Year Return

3164.TW
1.45%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
91.86%

Compare To: 3164.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3164.TW

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    1.75B

  • Enterprise Value

    1.41B

  • Trailing P/E

    44.89

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.75

  • Price/Book (mrq)

    1.33

  • Enterprise Value/Revenue

    3.81

  • Enterprise Value/EBITDA

    12.01

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.58%

  • Return on Assets (ttm)

    0.73%

  • Return on Equity (ttm)

    2.04%

  • Revenue (ttm)

    368.41M

  • Net Income Avi to Common (ttm)

    38.96M

  • Diluted EPS (ttm)

    0.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    388.42M

  • Total Debt/Equity (mrq)

    6.61%

  • Levered Free Cash Flow (ttm)

    53.8M

Research Analysis: 3164.TW

View More

Company Insights: 3164.TW

Research Reports: 3164.TW

View More

People Also Watch